Cost Efficient Clinical Trials for Today’s Economy-Adam Ruskin, PhD, DVM-06/16/2009 - 8:30am

Event Information
Event Topic: 
Cost Efficient Clinical Trials for Today’s Economy
Event Date: 
06/16/2009 - 8:30am
Event Location: 
Sunnyvale City Council Chambers, 456 West Olive Ave., Sunnyvale, CA
Speaker Information
Event Speaker: 
Adam Ruskin, PhD, DVM
Event Speaker Title: 
VP, Clinical Operations
Event Speaker Company: 
The Business Bridge
Event Speaker Bio: 

Adam Ruskin is VP of Clinical Operations for The Business Bridge CRO. Prior to joining his current company, Dr. Ruskin received a DVM degree and an MPH and PhD in Epidemiology. He created one of the first Electronic Data Capture (EDC) systems for the federal government in the early 1990s and was instrumental in standardizing the CDC’s national reportable infectious disease database. In the early 1990s he began speaking at industry conferences on efficient clinical trial design methodologies, which are now in common use today, as well as the usage of EDC in clinical trials before the internet was even in standard use. Over the past 5 years he has been the leading industry speaker on efficient clinical trial conduct. He has served as the global clinical lead and a business development representative for west-coast based Phase III trials for PPD. He later implemented efficient trial techniques at Cerexa which lead to successful pivotal trial results in record time and a company purchase of $500M, and again at Maxygen which lead to the lead drug candidate purchase for $120M. With over 50 clinical trials, Dr. Ruskin now heads up Clinical Operations at The Business Bridge, a CRO which has created further technological and cost-saving advances in EDC and implements all new cost and time saving methods for the most efficient clinical trials.

Event Details
$0 - Free
Event Details: 

Technological advances in drug research continue to dramatically increase the efficiency of the drug discovery process. Similar advances in drug development have also occurred with a plethora of new platforms in just the past 2-3 years. Selective applications of these new technologies are able to dramatically reduce development costs compared to just a few years ago, while simultaneously decreasing study start-up, conduct and database lock time while maintaining or improving database quality. Pharma, biotech and device companies, which have been implementing these practices, are noticing significant annual savings in cost, time and manpower. From protocols with quicker regulatory and ethics approvals, more accurate budgets, reduced contract approval times, elimination of the largest sources of cost overruns – low enrolling sites and missing laboratory samples, to advances in EDC, tracking of drug and study supplies, to rapid CDISC mapping, clinical development can now occur at a more cost and time efficient manner than ever.